Sanofi Opens Call for Proposals for 2025 iNext Awards North America
Sanofi has opened pre-proposal submissions for its 2025 iNext Awards, a pioneering program aimed at advancing high-risk, high-reward innovations in immunoscience. This initiative, led by Sanofi's External Scientific Affairs (ESA) team and Scientific Relations & Initiatives Pharma R&D, seeks "moonshot" ideas that push beyond conventional R&D and venture investment frameworks. Selected projects will receive up to $500,000 for an 18-month research program, supported by Sanofi’s R&D expertise.
Eligible participants include startups, academic laboratories, and university spin-offs in the U.S. and Canada with a focus on vaccine approaches for dyslipidemia and neuro-inflammation, as well as tolerogenic strategies for autoimmune and inflammatory diseases. Applicants must be at pre-seed through Series A stages with less than $1M in revenue and $10M in investments.
The pre-proposal submission deadline is January 30, 2025.
Applicants are required to detail their platform/technology, application to targeted disease areas, differentiation factors, and "moonshot" potential. Proposals must also confirm readiness for collaboration and compliance with Sanofi’s contracting processes.
For additional information or to access the application form, visit the Sanofi iNext Awards portal.
Questions can be directed to Parthiban Rajasekaran at parthiban.rajasekaran@sanofi.com or Laura Chambre at laura.chambre@sanofi.com.
